Cargando…

Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer

BACKGROUND AND PURPOSE: Several case reports and studies have suggested that there is an increased survival rate for patients who undergo resection of solitary adrenal metastasis from non-small cell lung cancer (NSCLC). This study aimed to investigate whether NSCLC patients with solitary adrenal met...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shao-Hong, Kong, Qing-Lei, Chen, Xue-Xia, He, Jin-Yuan, Qin, Jie, Chen, Zhuang-Gui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367455/
https://www.ncbi.nlm.nih.gov/pubmed/28356749
http://dx.doi.org/10.2147/TCRM.S130264
_version_ 1782517775819866112
author Huang, Shao-Hong
Kong, Qing-Lei
Chen, Xue-Xia
He, Jin-Yuan
Qin, Jie
Chen, Zhuang-Gui
author_facet Huang, Shao-Hong
Kong, Qing-Lei
Chen, Xue-Xia
He, Jin-Yuan
Qin, Jie
Chen, Zhuang-Gui
author_sort Huang, Shao-Hong
collection PubMed
description BACKGROUND AND PURPOSE: Several case reports and studies have suggested that there is an increased survival rate for patients who undergo resection of solitary adrenal metastasis from non-small cell lung cancer (NSCLC). This study aimed to investigate whether NSCLC patients with solitary adrenal metastasis could gain a higher survival rate after adrenalectomy (ADX) when compared with those patients undergoing nonsurgical treatment, and to investigate the potential prognostic factors. PATIENTS AND METHODS: A total of 1,302 NSCLC inpatients’ data from 2001 to 2015 were retrospectively reviewed to identify those with solitary adrenal metastasis. Overall survival for those who underwent both primary resection and ADX was compared to those patients with conservative treatment using the log-rank test. Potential prognostic variables were evaluated with univariate and multivariate analyses including clinical, therapeutic, pathologic, primary and metastatic data. RESULTS: A total of 22 NSCLC patients with solitary adrenal metastasis were identified, with an overall median survival of 11 months (95% confidence interval: 9.4–12.6 months) and a 1-year survival rate of 51.4% (95% confidence interval: 29.6%–73.2%). All of the patients had died by 30 months. There was no significant survival difference between patients who underwent primary and metastasis resection (n=10) and those treated conservatively (n=12), (P=0.209). Univariate analysis identified Eastern Cooperative Oncology Group performance status (ECOG PS) as the significant predictor of survival (P=0.024). Age (<65 vs ≥65 years), sex, pathologic type, mediastinal lymph node stage (N2 vs N0/N1), primary tumor size (<5 vs ≥5 cm), primary location (central vs peripheral), metastatic tumor size (<5 vs ≥5 cm), metastasis laterality, synchronous metastasis, and metastatic field radiotherapy were not identified as potential prognostic factors in relation to survival rate. In multivariate analysis, a stepwise selection procedure allowed both ECOG PS (P=0.007, relative risk =3.57) and pathologic type (P=0.069) to enter the Cox’s hazard function. CONCLUSION: Primary and metastatic radical resection may not prolong the survival of NSCLC patients with solitary adrenal metastasis. ECOG PS and pathologic type might be the prognostic factors for these patients.
format Online
Article
Text
id pubmed-5367455
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53674552017-03-29 Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer Huang, Shao-Hong Kong, Qing-Lei Chen, Xue-Xia He, Jin-Yuan Qin, Jie Chen, Zhuang-Gui Ther Clin Risk Manag Original Research BACKGROUND AND PURPOSE: Several case reports and studies have suggested that there is an increased survival rate for patients who undergo resection of solitary adrenal metastasis from non-small cell lung cancer (NSCLC). This study aimed to investigate whether NSCLC patients with solitary adrenal metastasis could gain a higher survival rate after adrenalectomy (ADX) when compared with those patients undergoing nonsurgical treatment, and to investigate the potential prognostic factors. PATIENTS AND METHODS: A total of 1,302 NSCLC inpatients’ data from 2001 to 2015 were retrospectively reviewed to identify those with solitary adrenal metastasis. Overall survival for those who underwent both primary resection and ADX was compared to those patients with conservative treatment using the log-rank test. Potential prognostic variables were evaluated with univariate and multivariate analyses including clinical, therapeutic, pathologic, primary and metastatic data. RESULTS: A total of 22 NSCLC patients with solitary adrenal metastasis were identified, with an overall median survival of 11 months (95% confidence interval: 9.4–12.6 months) and a 1-year survival rate of 51.4% (95% confidence interval: 29.6%–73.2%). All of the patients had died by 30 months. There was no significant survival difference between patients who underwent primary and metastasis resection (n=10) and those treated conservatively (n=12), (P=0.209). Univariate analysis identified Eastern Cooperative Oncology Group performance status (ECOG PS) as the significant predictor of survival (P=0.024). Age (<65 vs ≥65 years), sex, pathologic type, mediastinal lymph node stage (N2 vs N0/N1), primary tumor size (<5 vs ≥5 cm), primary location (central vs peripheral), metastatic tumor size (<5 vs ≥5 cm), metastasis laterality, synchronous metastasis, and metastatic field radiotherapy were not identified as potential prognostic factors in relation to survival rate. In multivariate analysis, a stepwise selection procedure allowed both ECOG PS (P=0.007, relative risk =3.57) and pathologic type (P=0.069) to enter the Cox’s hazard function. CONCLUSION: Primary and metastatic radical resection may not prolong the survival of NSCLC patients with solitary adrenal metastasis. ECOG PS and pathologic type might be the prognostic factors for these patients. Dove Medical Press 2017-03-23 /pmc/articles/PMC5367455/ /pubmed/28356749 http://dx.doi.org/10.2147/TCRM.S130264 Text en © 2017 Huang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Huang, Shao-Hong
Kong, Qing-Lei
Chen, Xue-Xia
He, Jin-Yuan
Qin, Jie
Chen, Zhuang-Gui
Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer
title Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer
title_full Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer
title_fullStr Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer
title_full_unstemmed Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer
title_short Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer
title_sort adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367455/
https://www.ncbi.nlm.nih.gov/pubmed/28356749
http://dx.doi.org/10.2147/TCRM.S130264
work_keys_str_mv AT huangshaohong adrenalectomydoesnotimprovesurvivalratesofpatientswithsolitaryadrenalmetastasisfromnonsmallcelllungcancer
AT kongqinglei adrenalectomydoesnotimprovesurvivalratesofpatientswithsolitaryadrenalmetastasisfromnonsmallcelllungcancer
AT chenxuexia adrenalectomydoesnotimprovesurvivalratesofpatientswithsolitaryadrenalmetastasisfromnonsmallcelllungcancer
AT hejinyuan adrenalectomydoesnotimprovesurvivalratesofpatientswithsolitaryadrenalmetastasisfromnonsmallcelllungcancer
AT qinjie adrenalectomydoesnotimprovesurvivalratesofpatientswithsolitaryadrenalmetastasisfromnonsmallcelllungcancer
AT chenzhuanggui adrenalectomydoesnotimprovesurvivalratesofpatientswithsolitaryadrenalmetastasisfromnonsmallcelllungcancer